In agreement, GLP1R agonists have been reported to reduce hepatocarcinogenesis in non-obese chemical carcinogen-induced mouse models of HCC, perhaps by limiting liver pro-tumorigenic metabolic factors such as hepatic insulin resistance, steatosis and inflammation90,91. This evidence concerns the gene INS and steatosis.